Physician profile
John K Ijem
NPI 1457353138
$9,149.17
in general payments reported to CMS, 2019-2025
41 companies · $1,110 in 2025
The $1,110 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,733 · 2020: $847 · 2021: $723 · 2022: $1,005 · 2023: $1,305 · 2024: $2,427 · 2025: $1,110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,892 · Travel and Lodging: $939 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,891.72 |
| Travel and Lodging | $939.41 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $1,970.46 | 2020-2025 | Barostim Neo System |
| Amgen INC. | $835.86 | 2019-2025 | Krystexxa, Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $738.78 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $626.46 | 2019-2025 | |
| Abbott Laboratories | $545.80 | 2019-2024 | Jot Dx, Assurity, Merlin@Home |
| Boston Scientific Corporation | $459.93 | 2019-2025 | Watchman Flx, Cds - Mct/Cem Monitoring, Bodyguardian |
| Janssen Pharmaceuticals, INC | $425.37 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $405.61 | 2021-2025 | Verquvo, Belsomra, Steglatro |
| E.R. Squibb & Sons, L.L.C. | $356.66 | 2019-2025 | Camzyos, Eliquis |
| Medtronic, INC. | $334.91 | 2021-2025 | Cobalt Dr Mri Surescan, Symplicity G3 |
| Astrazeneca Pharmaceuticals LP | $314.31 | 2019-2025 | Farxiga, Wainua |
| Boehringer Ingelheim Pharmaceuticals, INC. | $258.53 | 2019-2024 | Jardiance |
| Pfizer INC. | $256.18 | 2019-2025 | |
| Amarin Pharma, INC. | $171.68 | 2019-2022 | |
| Gilead Sciences, INC. | $150.11 | 2019-2020 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $135.17 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Horizon Therapeutics Plc | $116.56 | 2023 | Krystexxa |
| Daiichi Sankyo INC. | $96.50 | 2022-2024 | Injectafer |
| Davol INC. | $92.38 | 2025 | Phasix Mesh |
| Novo Nordisk INC | $77.50 | 2023-2024 | Rybelsus, Ozempic, Wegovy |
| Sanofi-Aventis U.S. LLC | $74.97 | 2021-2023 | |
| Alnylam Pharmaceuticals INC. | $74.35 | 2022-2023 | Onpattro |
| Regeneron Healthcare Solutions, INC. | $71.56 | 2019 | |
| Baxter Healthcare | $64.18 | 2023-2025 | Hillrom - Carnation Ambulatory Monitor |
| Actelion Pharmaceuticals US, INC. | $53.84 | 2019-2021 | |
| Bridgebio Pharma, INC. | $53.42 | 2025 | Attruby |
| Arbor Pharmaceuticals, INC. | $38.75 | 2019-2020 | |
| Glaxosmithkline, LLC. | $36.64 | 2024 | Arexvy, Shingrix |
| Scpharmaceuticals INC. | $34.25 | 2024-2025 | |
| Irhythm Technologies, INC. | $30.61 | 2022 | |
| Astellas Pharma US INC | $29.40 | 2019 | |
| Xeris Pharmaceuticals, INC. | $29.08 | 2022-2023 | Recorlev |
| Abbvie INC. | $28.75 | 2023 | |
| Kiniksa Pharmaceuticals International, Plc | $26.04 | 2024 | Arcalyst |
| Esperion Therapeutics, INC. | $23.33 | 2025 | Nexletol |
| Bardy Diagnostics, INC. | $22.63 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.81 | 2025 | |
| Cardinal Health 200 LLC | $19.15 | 2020 | |
| Preventice Services, LLC | $17.47 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $16.50 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $15.68 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ijem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.